A NEW OPTION for the prevention ofpostoperative nausea and vomiting – ALOXI.

This Web site is intended for U.S. residents only.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.
Distributed and marketed by Eisai Inc.
© 2008 Eisai Inc.
All rights reserved. ALP7 06/08

ALOXI® (palonosetron HCl) injection is indicated for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.

ALOXI is contraindicated in patients known to have hypersensitivity to the drug or any of its components. Most commonly reported adverse reactions include QT prolongation (5%), bradycardia (4%), headache (3%), and constipation (2%).